Overview

  • Product name

    anti-Nivolumab ELISA Kit (Opdivo®)
    See all Nivolumab kits
  • Detection method

    Colorimetric
  • Sample type

    Serum, Plasma
  • Assay type

    Sandwich (qualitative)
  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    anti-Nivolumab ELISA Kit (Opdivo®) (ab237665) is a highly specific and sensitive kit designed for the in vitro qualitative determination of antibody against Nivolumab in biological matrices such as human serum and plasma.


    Nivolumab (Opdivo®) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform

    Microplate

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 96 tests
    Assay Buffer 1 x 12ml
    Micro ELISA Plate 1 unit
    Negative Control 1 x 0.5ml
    Peroxidase Conjugate 1 x 12ml
    Plate sealers 2 units
    Positive Control 1 x 0.25ml
    Stop Solution 1 x 12ml
    TMB substrate 1 x 12ml
    Wash buffer (20X) 1 x 50ml
  • Relevance

    Nivolumab (Opdivo®) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models.
  • Alternative names

    • Opdivo

Applications

Our Abpromise guarantee covers the use of ab237665 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Protocols

References

ab237665 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab237665.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up